Validation of a [AlF]PSMA-11 preparation for clinical applications.

UNLABELLED

Imaging prostate-specific membrane antigen (PSMA) using positron emission tomography (PET) has been presented so far as the most sensitive and specific with regard to prostate cancer detection, in particular in high-risk prostate cancer patients. Currently, it mainly features Gallium-68 (Ga) labeled PSMA ligands, notably [Ga]Glu-urea-Lys(Ahx)-HBED-CC ([Ga]-PSMA-11) and [Ga]DOTAGA-FFK (Sub-KuE termed ([Ga]PSMA-I&T). However, Ga has several shortcomings as radionuclide including a short half-life and non-ideal energies. This has motivated consideration of F-labeled analogues for PET imaging of prostate cancer. Here, we describe a simple synthesis and validation of a fluorine-18 labeled Glu-urea-Lys(Ahx)-HBED-CC ([AlF]PSMA-11) for nuclear medicine applications. An efficient method for preparation of [AlF]PSMA-11 was developed and validated (according to Pharm Eur) for routinely clinical applications. [AlF]PSMA-11 was reproducibly obtained in radiochemical yields of 84 ± 6% (n = 15) and > 98% radiochemical purity using an improved one-step radiofluorination in aqueous solution. The total (production/preparation) time, including purification, pharmacological formulation of the isolated product and the quality control of the injectable solution was less than 60min. The [AlF]PSMA-11 was stable over 4h in 1% EtOH/saline selected as injection solution. The solution was sterile, non-pyrogenic and ready for clinical applications after sterile filtration through a 0.22µm membrane filter under sterile conditions. In addition, [AlF]PSMA-11 exhibited higher uptake and retention in PMSA-expressing LNCap prostate cells as compared to its clinically established Ga-labeled analogues [Ga]PSMA-11 and [Ga]PSMA-I&T as well as to [Ga]NOTA-Bn-PSMA. The simple and fast preparation of [AlF]PSMA-11 combined with its favorable pharmacological properties warrant its translation to a clinical setting.

CONCLUSION

The facile and high-yielding radiosynthesis of [AlF]PSMA-11as well as its promising in vitro and in-vivo characteristics makes it worthy of clinical development for PET imaging of prostate cancer.